Can the response to mood stabilizers be predicted in bipolar disorder?

Abstract : Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for the development of personalized therapies.
Type de document :
Article dans une revue
Front Biosci (Elite Ed), 2014, 6, pp.120-38
Liste complète des métadonnées

Littérature citée [79 références]  Voir  Masquer  Télécharger
Contributeur : Pierre Alexis Geoffroy <>
Soumis le : dimanche 23 février 2014 - 12:41:33
Dernière modification le : mardi 11 octobre 2016 - 15:17:02
Document(s) archivé(s) le : vendredi 23 mai 2014 - 10:41:34


Fichiers produits par l'(les) auteur(s)


  • HAL Id : inserm-00950859, version 1
  • PUBMED : 24389147



Pierre Alexis Geoffroy, Frank Bellivier, Marion Leboyer, Bruno Etain. Can the response to mood stabilizers be predicted in bipolar disorder?. Front Biosci (Elite Ed), 2014, 6, pp.120-38. 〈inserm-00950859〉



Consultations de la notice


Téléchargements de fichiers